| Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC M Mueller, A de la Peña, H Derendorf Antimicrobial agents and chemotherapy 48 (2), 369-377, 2004 | 408 | 2004 |
| Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study E Guttman-Yassky, JI Silverberg, O Nemoto, SB Forman, A Wilke, ... Journal of the American Academy of Dermatology 80 (4), 913-921. e9, 2019 | 334 | 2019 |
| Microdialysis in peripheral tissues A De la Peña, P Liu, H Derendorf Advanced drug delivery reviews 45 (2-3), 189-216, 2000 | 192 | 2000 |
| Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects A de la Peña, M Riddle, LA Morrow, HH Jiang, H Linnebjerg, A Scott, ... Diabetes care 34 (12), 2496-2501, 2011 | 155 | 2011 |
| Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro KM Rave, L Nosek, A De La Peña, M Seger, CS Ernest, L Heinemann, ... Diabetes care 28 (10), 2400-2405, 2005 | 105 | 2005 |
| Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes S Garg, J Rosenstock, BL Silverman, B Sun, CS Konkoy, A De La Peña, ... Diabetologia 49 (5), 891-899, 2006 | 89 | 2006 |
| Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials JS Geiser, MA Heathman, X Cui, J Martin, C Loghin, JY Chien, ... Clinical pharmacokinetics 55 (5), 625-634, 2016 | 82 | 2016 |
| Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus PA Kothare, H Linnebjerg, Y Isaka, K Uenaka, A Yamamura, KP Yeo, ... The Journal of Clinical Pharmacology 48 (12), 1389-1399, 2008 | 66 | 2008 |
| Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL A de la Peña, M Seger, D Soon, AJ Scott, SR Reddy, MA Dobbins, ... Clinical pharmacology in drug development 5 (1), 69-75, 2016 | 64 | 2016 |
| Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety EC Walvoord, A De La Peña, S Park, B Silverman, L Cuttler, SR Rose, ... The Journal of Clinical Endocrinology & Metabolism 94 (6), 2052-2059, 2009 | 63 | 2009 |
| Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes H Linnebjerg, PA Kothare, Z Skrivanek, A De La Peña, M Atkins, ... Diabetic medicine 23 (3), 240-245, 2006 | 62 | 2006 |
| PK–PD modelling of the effect of cefaclor on four different bacterial strains A de la Peña, A Gräbe, KH Rand, E Rehak, J Gross, U Thyroff-Friesinger, ... International journal of antimicrobial agents 23 (3), 218-225, 2004 | 46 | 2004 |
| CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial Y Jin, C Smith, D Monteith, R Brown, A Camporeale, TA McNearney, ... Osteoarthritis and cartilage 26 (12), 1609-1618, 2018 | 44 | 2018 |
| AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability K Rave, A De La Pena, FS Tibaldi, L Zhang, B Silverman, M Hausmann, ... Diabetes care 30 (7), 1777-1782, 2007 | 41 | 2007 |
| Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin A de la Peña, X Ma, S Reddy, F Ovalle, RM Bergenstal, JA Jackson Journal of diabetes science and technology 8 (4), 821-829, 2014 | 40 | 2014 |
| Methods and strategies for assessing uncontrolled drug–drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP … PL Bonate, M Ahamadi, N Budha, A de la Pena, JC Earp, Y Hong, ... Journal of pharmacokinetics and pharmacodynamics 43 (2), 123-135, 2016 | 30 | 2016 |
| The AIR® Inhaled Insulin System: System Components and Pharmacokinetic/Glucodynamic Data DB Muchmore, B Silverman, ADL Peña, J Tobian Diabetes technology & therapeutics 9 (S1), S-41-S-47, 2007 | 29 | 2007 |
| AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma M Wolzt, A de la Peña, PY Berclaz, FS Tibaldi, JR Gates, DB Muchmore Diabetes Care 31 (4), 735-740, 2008 | 28 | 2008 |
| Comparative Target Site Pharmacokinetics of Immediate‐and Modified‐Release Formulations of Cefaclor in Humans A de la Peña, M Brunner, HG Eichler, E Rehak, J Gross, ... The Journal of Clinical Pharmacology 42 (4), 403-411, 2002 | 23 | 2002 |
| Pharmacokinetic properties of beta-lactamase inhibitors. A De la Pena, H Derendorf International journal of clinical pharmacology and therapeutics 37 (2), 63-75, 1999 | 23 | 1999 |
